Press Releases ADC Therapeutics SA

Equities

ADCT

CH0499880968

Market Closed - Nyse Other stock markets 21:00:02 26/04/2024 BST			5-day change	1st Jan Change
4.34 ^USD	-2.25%		-8.05%	+161.45%

04-09	Transcript : ADC Therapeutics SA - Special Call
04-04	Sector Update: Health Care Stocks Slump Late Afternoon	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed, Refractory B-cell Non-Hodgkin Lymphoma	04-05	AQ
ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma	04-04	GL
ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024	04-03	GL
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan	04-01	GL
ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates	03-13	GL
ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting	03-06	AQ
ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes Summit	03-06	GL
ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes Summit	03-06	AQ
ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March 13, 2024	03-06	GL
ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting	03-05	GL
ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting	03-05	AQ
ADC Therapeutics : TD Cowen Healthcare Conference	03-05	PU
ADC Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference	02-27	GL
ADC Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference	02-27	AQ
ADC Therapeutics Regains Compliance with NYSE Continued Listing Standards	01-04	AQ
ADC Therapeutics Provides Business Updates	01-04	GL
ADC Therapeutics Regains Compliance with NYSE Continued Listing Standards	01-04	GL
Foresight Diagnostics Presents Four Presentations and Two Posters demonstrating accuracy and utility of PhasED-Seq ctDNA platform for early response assessment at the 65th American Society of Hematology	12-13	AQ
Thinking about buying stock in Crispr Therapeutics, Ardelyx, ADC Therapeutics, Acurx Pharmaceuticals, or Sphere 3D?	12-12	PR
ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA® in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL)	12-12	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases ADC Therapeutics SA

Equities

ADCT

CH0499880968

Press Releases

Filters